Koninklijke Philips N.V. PHG reported earnings of €0.08 cents per share in the first quarter of 2025, which increased from the year-ago quarter’s loss of €1.07 per share. The company’s sales decreased 1% on a year-over-year basis to €4.1 billion. Comparable sales declined 2% year over year, including a double-digit decline in China. The 1% growth in Personal Health was more than offset by a 4% decline in Diagnosis & Treatment on the back of a high comparison base. Connected Care sales were in line with the prior year. Further, Philips’ comparable order intake increased 2% year over year in the reported quarter despite a double-digit decline in China. Koninklijke Philips N.V. Price, Consensus and EPS SurpriseKoninklijke Philips N.V. Price, Consensus and EPS Surprise Koninklijke Philips N.V. price-consensus-eps-surprise-chart | Koninklijke Philips N.V. Quote Sales declined 4% year over year on a comparable basis in growth geographies. Growth geographies primarily decreased as a result of a double-digit decline in China and a high comparison base in Diagnosis & Treatment. The decline was partly offset by an increase in other Growth geographies. Comparable sales in Mature geographies declined 2% year over year, mainly due to a high comparison base in Diagnosis & Treatment. PHG’s Segmental Update Diagnosis & Treatment revenues declined 3% year over year from the year-ago quarter to €1.96 billion. Comparable sales declined 4% year over year, primarily due to a double-digit decline in China, which was offset by strong growth in other regions. While Image Guided Therapy saw solid growth, it was offset by a decline in Precision Diagnosis. Connected Care revenues increased 1.5% year over year to €1.18 billion. Comparable sales were flat from the year-ago quarter. Personal Health revenues grew 3% year over year to €811 million. Comparable sales increased 1%, despite a double-digit decline in China, mainly driven by strong growth across the International Region and slight growth in the United States. Other segment sales amounted to €140 million, down 10.8% on a year-over-year basis. PHG’s Operating Details Gross margin expanded 130 basis points (bps) on a year-over-year basis to 45.1% in the reported quarter. General & administrative expenses, as a percentage of sales, were 3.9%, which expanded 60 bps on a year-over-year basis. Moreover, selling expenses were flat year over year at 26.5%. Research & development expenses increased 100 bps to 11.2%. Restructuring, acquisition-related and other items amounted to a net gain of €143 million compared with €1,139 million a year ago. Operating model productivity, procurement and other productivity programs delivered savings of €42 million, €46 million and €59 million, respectively. This resulted in total savings of €147 million. Phillips’ adjusted EBITA — the company’s preferred measure of operational performance — declined 8.8% year over year to €354 million. EBITA margin contracted 80 bps on a year-over-year basis to 8.6% in the reported quarter. Diagnosis & Treatment’s adjusted EBITA margin expanded 30 bps on a year-over-year basis to 9.5%. Connected Care’s adjusted EBITA margin was 3.5% in the reported quarter, which contracted 290 bps year over year. Personal Health’s adjusted EBITA margin remained in line on a year-over-year basis at 15.2%. Story Continues PHG’s Balance Sheet As of March 31, 2025, Philips’ cash and cash equivalents were €1.19 billion compared with €2.4 billion as of Dec. 31, 2024. Total debt was €7.568 billion compared with €7.639 billion as of Dec. 31, 2024. Operating cash outflow was €933 million compared with the year-ago quarter’s operating cash outflow of €171 million. In the quarter under review, free cash outflow was €1,091 million compared with the year-ago quarter’s free cash outflow of €336 million. PHG Initiates Weak 2025 Guidance Philips stock has lost 4.8% year to date compared with the Zacks Medical sector’s decline of 2.4%. PHG’s 2025 guidance can be negatively impacted by announced tariffs, including US-China and global measures, and the scheduled resumption of US tariffs on July 9. These factors may also put downward pressure on PHG’s shares. Philips expects to deliver 1-3% of comparable sales growth. Further, the adjusted EBITA margin is expected to be between 10.8% and 11.3% Free cash flow is expected to be slightly positive in 2025, after the payout of €1,025 million Philips Respironics recall-related medical monitoring and personal injury settlements in the United States. Previously, Philips expected to deliver 1-3% of comparable sales growth. Further, adjusted EBITA margin is expected to be 30-80 bps to 11.8%-12.3% Philips expects a free cash flow of €900 million. PHG’s Zacks Rank & Stocks to Consider Philips currently has a Zacks Rank #3 (Hold). Affirm AFRM, ACI Worldwide ACIW and Baidu BIDU are some better-ranked stocks that investors can consider in the broader sector. While Affirm sports a Zacks Rank #1 (Strong Buy), ACI Worldwide and Baidu presently carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here. Affirm shares have lost 16.3% year to date. AFRM is set to report its third-quarter fiscal 2025 results on May 25. ACI Worldwide shares have gained 4.9% year to date. ACIW is set to report its first-quarter 2025 results on May 08. Baidu shares have gained 8.2% year to date. BIDU is set to report its first-quarter 2025 results on May 21. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Koninklijke Philips N.V. (PHG):Free Stock Analysis Report Baidu, Inc. (BIDU):Free Stock Analysis Report ACI Worldwide, Inc. (ACIW):Free Stock Analysis Report Affirm Holdings, Inc. (AFRM):Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research
Philips Q1 Earnings Miss: Will Weak Outlook Drag the Stock Down?
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...